Immunic

The ENSURE program includes two phase 3 trials evaluating vidofludimus calcium's efficacy and safety in RMS patients, with primary endpoints focusing on relapse time and disability progression. Concurrently, the phase 2 CALLIPER trial assesses its neuroprotective potential in PMS patients. Positive interim data from both trials suggest vidofludimus calcium's effectiveness beyond anti-inflammatory effects, with potential regulatory approval in RMS and implications for PMS treatment.

MS, an autoimmune disease affecting 2.9 million globally, varies greatly in symptoms and course. Immunic, a biotech company, is developing vidofludimus calcium, a selective immune-modulator, for MS treatment. The drug targets Nurr1 for neuroprotective effects and inhibits DHODH for anti-inflammatory and antiviral effects. Immunic anticipates Phase 3 trial results in 2026, focusing on relapsing MS, and Phase 2 results for progressive MS in 2025, aiming for potential accelerated approval.

DelveInsight's 2024 report highlights over 100 companies and drugs in the Multiple Sclerosis (MS) pipeline, including AstraZeneca, Biogen, and Novartis. It covers MS's autoimmune nature, treatment advancements, and ongoing clinical trials, such as Roche's Phase 3 studies on Ocrelizumab and Fingolimod for pediatric MS. The report emphasizes the importance of early diagnosis and the development of therapies targeting MS's progression and symptoms.

The 'Multiple Sclerosis - Pipeline Insight, 2024' report by ResearchAndMarkets.com covers 80+ companies and 85+ pipeline drugs, including IMU-838 (Immunic), Masitinib (AB Science), Foralumab (Tiziana Life Sciences), IMCY-0141 (ImCyse), and BMS-986353 (Bristol-Myers Squibb). It provides insights into clinical and nonclinical stage products, therapeutics assessment, and pipeline development activities.

Tulisokibart, an anti-TL1A monoclonal antibody, outperformed placebo in inducing clinical remission at week 12 in moderate to severe ulcerative colitis, according to the ARTEMIS-UC trial. The study incorporated a predictive biomarker for response, showing significant clinical remission, endoscopic improvement, and clinical response in patients on tulisokibart compared to placebo. A phase 3 program is planned to confirm these results.

The 'Crohn's Disease - Pipeline Insight, 2024' report by ResearchAndMarkets.com provides insights on 70+ companies and 80+ pipeline drugs, including clinical and nonclinical stage products, therapeutic assessments, and emerging drugs like Ozanimod, Etrasimod, CBP-307, and IMU-856. The report highlights the current scenario and growth prospects in Crohn's Disease treatment, focusing on novel approaches and key players in the field.

Vidofludimus calcium showed promising results in reducing neurofilament light chain levels in MS patients, suggesting neuroprotective and anti-inflammatory effects. It also demonstrated potential in reducing fatigue by preventing Epstein-Barr virus reactivation, with ongoing trials to confirm these benefits.

First patient enrolled in a phase 2 trial of vidofludimus calcium for Post COVID Syndrome, aiming to reduce inflammation and fatigue, with potential to prevent Epstein-Barr virus reactivation.

Immunic, Inc. enrolls first patient in phase 2 trial of vidofludimus calcium for Post COVID Syndrome, aiming to reduce fatigue and Epstein-Barr virus reactivation, with potential implications for multiple sclerosis treatment.